echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NICE recommends Merck's Tepmetko (tepotinib) for lung cancer

    NICE recommends Merck's Tepmetko (tepotinib) for lung cancer

    • Last Update: 2022-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The UK National Institute for Health and Care Excellence (NICE) recommends Tepmetko (tepotinib) for the treatment of adult patients with advanced non-small cell lung cancer ( NSCLC


    Lung cancerNSCLC

    Tepotinib is the first and only oral MET inhibitor recommended for the treatment of adult patients with advanced NSCLC with a METex14 skipping mutation for the NHS in England, Wales and Northern Ireland


    Dr Shobhit Baijal, Consultant Medical Oncologist, University Hospitals NHS Trust, Birmingham, explained: "Existing treatment options for patients with METex14 skipping mutations often show limited progression-free survival and overall survival benefit


    NSCLC is a heterogeneous disease with many genomic mutations


    In an open-label phase II study, tepotinib (500 mg) was administered to patients with advanced or metastatic NSCLC with METex14 skipping mutations


    In the combined biopsy group, the independently reviewed ORR was 46%, and the median duration of response was 11.


     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https://


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.